EBC-46

Seasonal Yield and Tigilanol Tiglate Concentration: What Drives Variation in Blushwood Fruit Chemistry

Tigilanol tiglate concentration in Fontainea picrosperma fruit varies with season, rainfall, plant maturity, and growing environment — a fact with profound implications for supply chain and cultivation strategy.

EBC-46

Dose Escalation in Tigilanol Tiglate Trials: Optimising the Intratumoral Injection

Determining the right intratumoral dose of tigilanol tiglate required solving problems unique to locally-delivered agents — from volume calculation to defining dose-limiting toxicity at the injection site.

EBC-46

Apoptosis vs Necrosis: How EBC-46's Cell Death Pathway Differs from Conventional Chemotherapy

EBC-46 kills cancer through a dual mechanism — activating both apoptotic programming and catastrophic vascular necrosis — that conventional chemotherapy cannot replicate and the immune system amplifies.

EBC-46

Breakthrough Therapy Designation: Could Tigilanol Tiglate Qualify and What Would It Mean?

Breakthrough Therapy Designation compresses development timelines dramatically. Here's how tigilanol tiglate stacks up against the FDA's criteria — and what qualifying would mean for patients.

EBC-46

Skin Lesions, Moles, and Topical Application: What Blushwood Berry Extract Users Are Reporting

Verified buyers report moles falling off, rashes resolving, and skin texture improving after topical application of blushwood berry tincture — observations consistent with PKC-mediated dermal biology that deserve rigorous investigation.

EBC-46

From Rainforest Fruit to Pharmaceutical Compound: How Tigilanol Tiglate Is Extracted from the Blushwood Berry

Extracting tigilanol tiglate from the Blushwood berry is a multi-stage process that bridges traditional plant chemistry and modern pharmaceutical science — and the full phytochemical picture is still emerging.

EBC-46

Combining Tigilanol Tiglate with Checkpoint Inhibitors: The Rationale for Dual-Mechanism Oncology Trials

By triggering rapid local immune activation, tigilanol tiglate may prime the tumour microenvironment for checkpoint inhibitor therapy — a combination strategy now attracting serious clinical investigation.

EBC-46

PKC Isoforms and Mitochondrial Energy Metabolism: How EBC-46 May Influence Cellular Energetics

Protein kinase C isoforms activated by EBC-46 are intimately connected to mitochondrial function — a link that may explain both anti-tumour effects and the energy-related reports from supplement users.

EBC-46

Intratumoral Drug Approvals: The Unique Regulatory Challenges Facing EBC-46

Intratumoral drugs like tigilanol tiglate must satisfy regulatory requirements that conventional systemic cancer therapies were never designed to address — from injection site assessment to lesion-level endpoints.

EBC-46

Energy, Inflammation, and Systemic Wellbeing: The Blushwood Berry Extract Testimonial Pattern

Across dozens of verified buyer accounts, a consistent pattern emerges: reduced inflammation, increased energy, and improved systemic wellbeing — observations that align remarkably with what we know about PKC signalling biology.

EBC-46

Indoor Cultivation of Fontainea picrosperma: What Growers Beyond Queensland Have Learned

While Fontainea picrosperma grows wild only in north Queensland's rainforests, cultivators in controlled indoor environments across Australia and Asia are proving the species thrives well beyond its native range.

EBC-46

Head and Neck Squamous Cell Carcinoma and EBC-46: What the Phase II Data Reveals

Phase II trials targeting cutaneous head and neck squamous cell carcinoma with intratumoral tigilanol tiglate show measurable responses in accessible lesions and a well-characterised safety profile.